Member Info for Barnacle

Once the QVH contract has been awarded, and based on data from the the pilot, it has to go to Feedback, I believe the number of new contracts won will begin to accelerate rapidly, as mentioned in the results:

With over 174 CDCs now approved and under construction, Feedback has a growing market to sell into. At a target contract value of £400k - £600k/annum per CDC on average, this creates a sizeable opportunity for the Company. Having worked on a pilot with QVH/Sussex ICS for over two years, the Company is now awaiting the results of the current procurement process which will soon complete. The rest of the NHS will be closely following the outcome of the QVH/Sussex ICS procurement process, and management is optimistic that success here would lead to more rapid contract conversion at other sites.

And more:

"Key milestones in the upcoming period will be the outcome of the QVH/Sussex ICS procurement which is anticipated to lead to further business within the southeast region if converted, successful delivery of the current pilots utilising central funds disbursed by NHSE with a view that this will unlock both contracts and further potential pilots in new areas in the coming NHS financial year (April 2024 onwards), and the conversion of a deep and growing sales pipeline of both local and regional opportunities."

Now that Feedback has the evidence that Bleepa is saving time and money, at both QVH and the NCA, I believe we will start seeing more contracts being awarded over the coming months. I like this paragraph from the report:

With over 174 CDCs now approved and under construction, Feedback has a growing market to sell into. At a target contract value of £400k - £600k/annum per CDC on average, this creates a sizeable opportunity for the Company. Having worked on a pilot with QVH/Sussex ICS for over two years, the Company is now awaiting the results of the current procurement process which will soon complete. The rest of the NHS will be closely following the outcome of the QVH/Sussex ICS procurement process, and management is optimistic that success here would lead to more rapid contract conversion at other sites.

Feedback Medical's digital innovation in the clinical communication space is further endorsed by the World Innovation Congress by conferring our India Managing Director, Rohit Singh with the Innovation Leadership Award at the 16th Edition of World Innovation Congress 2024 on 18th February 2024 at the Taj Lands End, Mumbai.

The fact that they have been awarded the pilot funding to undertake further CDC pathway development at Amersham CDC in Buckinghamshire and a pan regional pilot across Buckinghamshire, Oxfordshire and Berkshire ICS, suggests that they have been successful with the QVH tender, in my opinion.

I hope everyone has submitted their questions for Wednesday's Investor Presentation... Maybe we'll get some additional news......

Norfolk and Norwich University Hospitals NHS Foundation Trust was listed as being a Partner of Feedback in previous presentations.

Provider collaboratives building diagnostic capacity – NHS Providers

In their first instalment of their new series ‘Provider collaboratives building capacity’, NHS Providers shares case studies from Cheshire and Merseyside and Norfolk and Waveney.

“While the £2.3 billion allocated by the government to support the establishment of CDCs was very welcome, it is a limited sum given the scale of expansion needed in diagnostics across the country,” NHS providers say among the key findings.

“However, it has helped providers to come together to jointly plan and provide CDCs. One driver for providers to collaborate on diagnostics has been to strengthen their bids for this funding, by demonstrating the impact increased investment would have on system-wide performance and the ability to meet system targets.”

With the largest concentration of CDCs in the country, Cheshire and Merseyside share how collaborative working has helped their diagnostics programme to achieve a 21% increase in activity across all key diagnostic tests.

Norfolk and Waveney ICS share how their collaborative programme across three acute trusts is aiming to improve access to faster diagnosis and build diagnostic capacity.

Interesting ............

In the first edition of our community diagnostic centre news roundup: recommendations from the Patient’s Association for better access to diagnostic services, a review of effectiveness and cost-effectiveness of CDCs, and case studies from NHS Providers.

Read the full round-up here:

https://bleepa.com/community-diagnostic-centre-roundup

Looking good - "The Board is pleased to report a strong performance during the second half of FY23, with total unaudited revenue for FY23 being slightly above market expectations, at approximately £5.8 million (2022 restated: £4.7 million), due to particularly strong Brand Experience revenue, the successful launch of our Rock Up and Pop Up service and the continued recovery and expansion of our German retail business."

As the Group's products and services continue to evolve, during FY23, the Group reassessed its revenue recognition policies in its UK retail division. Previously, all revenue within the UK retail division was recognised on a gross basis, as it was deemed to have one performance obligation. Following this reassessment, it is now considered that there are two separate performance obligations:

(i) acting as the promotional space agent which involves the marketing of space to licensees and entering into and managing licence agreements on behalf of venues as their agent; and

(ii) the short-term rental of the Group's own kiosks.

Accordingly, UK retail revenue will now be recognised on a net basis in FY23, with FY22 comparative figures being restated. Under the new revenue recognition policy, market expectations for FY23 revenue should therefore be adjusted from £6.5 million to £5.7 million. The reassessment does not impact reported profits.

In terms of balance sheet, as at 31 December 2023, the Group had cash of £1.9 million (2022: £1.9 million) with £1.1 million of term loans (2022: £1.5 million) and undrawn bank facilities of £0.7 million (2022: £0.7 million). Therefore, total cash available as at 31 December 2023 was £2.6 million (2022: £2.2 million).

The Group expects to announce its FY23 results during the week commencing 29 April 2024.

BACKGROUND

Heart Scent is a Glasgow-based gifting retailer established in 2012 that has retailed within The Forge Shopping Centre, Glasgow since 2013. Heart Scent retail a wide selection of gifting products, many of which are handmade, or hand finished. Their range includes home décor, home fragrance and floral gifts

AIMS & OBJECTIVES

Expand retail presence into one of Glasgow’s top shopping venues

Grow customer base in Glasgow and surrounding area

EXECUTION

Utilise SpaceandPeople’s Rock Up and Pop Up service to open second physical location in one of Glasgow’s top shopping venues, Braehead Centre

RESULTS

Heart Scent have now been operating successfully within Braehead Centre since Spring 2022

Consistent sales results within Braehead Centre, averaging £10,700 monthly

Expansion of personalised product line with many items being available on the same day as purchase

Introduction of popular click and collect service for custom orders

“The opening of our second location with the help of Rock Up and Pop Up was a pivotal moment for Heart Scent’s growth as a business and we have received such a great response from customers in Braehead Shopping Centre. Meeting new customers at our second location has allowed us to gain great feedback and ideas which has led us to launching new product lines including an expanded personalised artworks range.

– Karen, Heart Scent

We are pleased to announce our latest winner for Retailer of the Month is Ishvari by Renu Modha!

We began working with textile brand Ishvari by Renu Modha in mid-2023 to expand their physical retail presence in the UK. The retailer had previously hosted pop-up concessions and were eager to launch their own pop-up in the UK. Ishvari by Renu Modha used our Rock Up and Pop Up service to trial some of the UK’s top shopping venues and have now been successfully retailing within Westfield London since October 2023. Their range of bright and beautiful scarves and accessories have been a big hit with shoppers at Westfield London and are attractively merchandised on their monochromic pop-up shop. The retailer had a busy festive season that has continued into the new year with new products continually being added to their range.

Here’s what Renu had to say about their journey with Rock Up and Pop Up:

“Rock Up and Pop Up has enabled our brand to retail in some amazing locations in 2023 including The Trafford Centre and Westfield London! We’ve been able to showcase our eye-catching range perfectly from our branded pop-up and are looking forward to meeting new customers this year.”

We’re delighted that Ishvari by Renu Modha will be continuing to retail with Rock Up and Pop Up at Westfield London in 2024 - well done team!

Might mean nothing, but Lars has liked this post by Allenby Capital, seems a bit unusual...

"Allenby Capital is delighted to have advised Location Sciences on its reverse takeover of Sorted Holdings, the SaaS business providing delivery experience software for ecommerce retailers."

Could there be a reverse takeover of Cap-xx ?

A reverse merger is an attractive strategic option for managers of private companies to gain public company status.

It is a less time-consuming and less costly alternative to the conventional initial public offerings (IPOs).

Public company management enjoy greater flexibility in terms of financing alternatives, and the company's investors enjoy greater liquidity.

Public companies face additional compliance burdens and must ensure that sufficient time and energy continues to be devoted to running and growing the business.

A successful reverse merger can increase the value of a company's stock and its liquidity.

I would think that the £6.5m guidance will be pretty accurate. Listening back to the previous Investor Meet Presentation, I feel that there are a lot of positives, and room for further growth. Seems to be a well run company in my eyes.

https://www.youtube.com/embed/JclwXAzKD24

The run up to Christmas should have been good in both the UK, Germany and Austria.

In Germany, The new Trading Agreement with Multi, opened up the prospect of an additional 10 venues. They are also looking to expand into other neighbouring countries, so again, good potential for overseas growth in this area.

There is also an 'endless demand' for Rock Up and Pop Up, and the company were in going to 'more than double' the RUPU offering in H2 so this should again increase revenues.

They are also looking to grow the Network Rail business, so I can only see this relationship strengthening.

Moving forward, bar another pandemic, I can only see revenues continuing to grow, profits increasing, and as you say, at a Market Cap of only £1.14m the shares look extremely cheap......

I'm expecting a positive trading update.

Https://experientialspace.co.uk/a-selection-of-2023-christmas-activations/

Three directors bought shares in the last placing at 1.3p. Their visibility of how the business is progressing indicates confidence going forward. Lots to look forward to.

The following directors of the Company, and therefore each a related party as defined in the AIM Rules for Companies,

participated in a subscription of new ordinary shares in the Company on 4 May 2023 (the “Subscription”):

Patrick Elliot, the Company’s Chairman, subscribed for 3,846,154 new ordinary shares in the Subscription,

which represented an amount of £50,000 at the Subscription’s issue price of 1.3 pence per new ordinary share

(the “Issue Price”).

Bruce Grey, one of the Company’s Non-Executive Directors, subscribed for 2,307,692 new ordinary shares in

the Subscription, which represented an amount of £30,000 at the Issue Price.

Anthony Kongats, the Company’s previous CEO, subscribed for 4,615,385 new ordinary shares in the

Subscription, which represented an amount of £60,000 at the Issue Price.

From Linkedin:

Feedback Medical is excited to be exhibiting at the Association of Healthcare Providers - AHPI (India) for their 11th Global Conclave 2024 on February 2-3rd. Come and visit us on stand 5 for a hands on look at our clinical communications platform Bleepa !

From RNS - 10 January 2024:

On 27 December 2023, the Delaware District Court entered judgment in favour of Maxwell Technologies in a patent infringement case asserted by CAP-XX. While CAP-XX is disappointed with the result, it is evaluating all options, including making an appeal to the Federal Circuit Court of Appeals.

Https://etech49.com/episode-96-lars-stegmann-capxx/

Well worth a read:

https://www.rcr.ac.uk/news-policy/policy-reports-initiatives/representing-your-voice-in-uk-parliaments/cdcs-unveiled-challenges-and-triumphs/

An extract from the Report, Point 4 is basically describing Bleepa.....

Physical and digital infrastructure

Ensuring CDCs are equipped with up-to-date machines is crucial for accurate and efficient diagnostic procedures. NHSE are committed to providing new equipment for CDCs and are actively monitoring the condition of machines to maintain a high standard of care.

Digital tools, such as the iRefer tool and NHS App, are vital to streamlining diagnostics, improving efficiency and patient engagement. Unfortunately, despite pilot programmes like Feedback Medical’s digital infrastructure solutions at Queen Victoria Hospital showing significant gains, challenges with basic infrastructure and data sharing, plus inconsistent

digital advancements, persist, underscoring the need for additional funding for robust digital infrastructure.

1. NHSE should provide more centralised digital leadership by developing a national strategy for the integration of patient data and digital tools within CDCs. This strategy should outline a roadmap for the adoption of digital solutions,

including clinical decision support systems, to streamline the diagnostic process.

2. After CDC approval, system leads should conduct outreach with primary care providers within the ICS to increase awareness of the new site. If patient referrals from these providers do not reach the expected level, leads should

engage in personalised outreach. This approach addresses misconceptions, resolves hesitations, and tailors communication to improve collaboration for effective CDC integration in healthcare.

3. NHSE should prioritise bolstering digital infrastructure and patient data sharing in CDCs. Periodic assessments should be conducted to address integration challenges.

4. NHSE should develop and enforce interoperability standards for digital tools used within CDCs to ensure seamless data exchange and collaboration between primary and secondary care settings. This standardisation will enable clinicians to access patient information across different points of care, improving coordination and decision-making.